WOBURN, Mass., Sept. 26 /PRNewswire/ -- BioProcessors Corporation, a leading innovator of high-throughput cell culture-based solutions for biopharmaceutical process development, expands its Woburn operations and launches new SimCell Services offering.
"We continue to see strong interest in our SimCell technology," said Jonathan Rennert, President and CEO, BioProcessors Corporation. "The biopharmaceutical industry is accelerating its pace to clinical trials in order to identify successful therapeutic candidates sooner. Expanding our capacity and scope allows the company to respond more quickly and effectively to this key market need."
A second SimCell System was recently installed as part of an expanded laboratory and training wing at BioProcessors' Woburn facility. "Two high- throughput Robotic Systems, along with supporting analytical instrumentation and a new multi-media customer training center, provide our new team of cell culture specialists with much more comprehensive applications development and training capabilities," added Rennert. "We are now positioned to expand customer access to SimCell technology through the introduction of our new SimCell Services."
SimCell Services are customized service offerings tailored to meet specific cell culture application requirements of BioProcessors' clients. They provide access to SimCell technology through a hosted cell culture development project, which can range in scope from a simple screening experiment to more comprehensive production clone selection, clone stability, media optimization, or process development experiments. SimCell Services help clients gain better insight into their bioprocesses and reduce development risk by enabling the design of robust, optimized bioprocesses, faster and more efficiently.
About BioProcessors Corporation
BioProcessors Corporation is a developer and provider of micro-engineered solutions for cell culture-based upstream bioprocess development. The Company's SimCell technology provides the capability to perform high throughput cell culture experiments for the development and optimization of biopharmaceutical manufacturing processes. The high throughput capability of the system enables execution of full and fractional factorial statistical experiments at a fraction of the time and cost associated with conventional scale-down technologies. The result is greater insight and reduced risk for bioprocess development decision making.
For more information on BioProcessors Corporation, contact Eric Denoyer, Marketing Director, BioProcessors Corporation +1 781-305-8867, firstname.lastname@example.org, or visit www.bioprocessors.com.